MedTrace Logo

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

NCT00088478 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2007-06-12

No results posted yet for this study

Summary

Key objectives of this clinical study are to:

* Determine how well intramuscular (IM) olanzapine depot works compared to placebo
* Evaluate the safety and tolerability of IM olanzapine depot compared to placebo
* Evaluate different doses of IM olanzapine depot compared to placebo to identify the best dose(s).

Conditions

Interventions

DRUG

Intramuscular Olanzapine Depot

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2005-04-30

Countries

  • United States
  • Croatia
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00088478 on ClinicalTrials.gov